MDM2 and acute myeloid leukemia: As there was no apparent correlation of NPM1 gene status with idasanutlin sensitivity in FLT3wt AML cells, we hypothesized that susceptibility to the MDM2 inhibitor may depend on the abundance of the target protein in the AML cells.